503 b pharmacy tirzepatide The FDA has proposed to bar 503B outsourcing facilities from bulk compounding semaglutide and tirzepatide. The shortage-list pathway already closed in 2024 and 2025; this proposal would remove the remaining bulks-list route 503A vs. 503B Compounding Pharmacies

MOTS-c mitochondrial peptide therapy in Beverly Hills may support cellular energy, insulin sensitivity and healthy aging

It's arguably one of the more important electrolyte disorders, since a potassium level thats out of whack can quickly lead to fatal heart arrhythmias.

Find FAQs and resources for your GLP-1 journey.

Support your weight loss journey with medically supervised programs at BHRC, including customized plans that help optimize metabolism, fat reduction, and long-term success.

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027